Bakker Juliet Tammenoms
CIK 1431159 · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RXST price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
800 EL CAMINO REAL, SUITE 220
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RXST | Director | 86,731 | $4.80 | $416.3K | -$13.82M | 18 | 2026-06-18 |
| CBLL | Director | 2,498,394 | $26.96 | $67.36M | $4.03M | 3 | 2026-06-04 |
| VERA | 10%+ Owner | 1,714,285 | $30.25 | $51.86M | $12.00M | 1 | 2023-02-08 |
| Sierra Oncology, Inc. (SRRA) Delisted | 10%+ Owner | 175,000 | $54.99 | $9.62M | $4.72M | 3 | 2022-02-02 |
| RPID | 10%+ Owner | 150,000 | $0.70 | $105.4K | $3.00M | 1 | 2021-07-20 |
| Eargo, Inc. (EAR) Delisted | Director | 96,286 | $2.57 | $247.5K | $4.20M | 4 | 2021-05-19 |
| Tourmaline Bio, Inc. (TALS) Delisted | 10%+ Owner | 298,578 | $27.20 | $8.12M | $4.00M | 1 | 2021-05-11 |
| AXNX | Director | 783,533 | $1.00 | $783.5K | $7.51M | 9 | 2020-09-22 |
| Molecular Templates, Inc. (MTEM) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $7.46M | 2 | 2020-09-01 |
| Venus Concept Inc. (HAIR) Delisted | Director | 231,772 | — | — | $0 | 1 | 2019-11-07 |
| Tricida, Inc. (TCDA) Delisted | 10%+ Owner | 3,019,734 | $0.11 | $326.1K | $2.50M | 1 | 2018-07-02 |
| Aptinyx Inc. (APTX) Delisted | 10%+ Owner | 1,047,450 | $0.06 | $63.9K | $2.40M | 1 | 2018-06-26 |
| COLL | 10%+ Owner | 6,029,785 | $23.68 | $142.79M | $2.70M | 2 | 2018-02-26 |
| CORT | Director | 10,874,259 | $80.46 | $874.94M | $2.92M | 4 | 2016-12-19 |
| Esperion Therapeutics, Inc. (ESPR) Delisted | 10%+ Owner | 37,757 | $3.18 | $120.1K | -$386.6K | 2 | 2014-10-14 |
Recent Filings · Page 6 of 6
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-12-19 | CORT | Gift (G) | −70,671 | $0 | EDGAR |
| 2016-12-14 | CORT | Other (J) | +204,210 | $0 | EDGAR |
| 2016-11-30 | CORT | Other (J) | −3,000,000 | $0 | EDGAR |
| 2015-05-14 | COLL | Mixed | +3,321,842 | $2.40M | EDGAR |
| 2014-10-14 | Esperion Therapeutics, Inc. (ESPR) Delisted | Sell (S) | −943 | -$28.3K | EDGAR |
| 2014-10-09 | Esperion Therapeutics, Inc. (ESPR) Delisted | Sell (S) | −11,927 | -$358.3K | EDGAR |
| 2011-01-25 | CORT | Buy (P) | +750,000 | $2.92M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.